These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 23934201

  • 1. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J, Eichner S, Zeilinger C, Kirschning A.
    Nat Prod Rep; 2013 Oct 11; 30(10):1299-323. PubMed ID: 23934201
    [Abstract] [Full Text] [Related]

  • 2. Rational design and synthesis of ansa-adenosines as potential antitumor agents.
    Muranaka K, Ichikawa S, Matsuda A.
    Nucleic Acids Symp Ser (Oxf); 2009 Oct 11; (53):5-6. PubMed ID: 19749232
    [Abstract] [Full Text] [Related]

  • 3. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
    Khandelwal A, Crowley VM, Blagg BSJ.
    Med Res Rev; 2016 Jan 11; 36(1):92-118. PubMed ID: 26010985
    [Abstract] [Full Text] [Related]

  • 4. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C, Lang SA, Stoeltzing O.
    Anticancer Res; 2009 Jun 11; 29(6):2031-42. PubMed ID: 19528462
    [Abstract] [Full Text] [Related]

  • 5. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G, Caldas Lopes E, Solit D.
    Curr Opin Investig Drugs; 2006 Jun 11; 7(6):534-41. PubMed ID: 16784024
    [Abstract] [Full Text] [Related]

  • 6. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
    Hadden MK, Lubbers DJ, Blagg BS.
    Curr Top Med Chem; 2006 Jun 11; 6(11):1173-82. PubMed ID: 16842154
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
    Lee K, Ryu JS, Jin Y, Kim W, Kaur N, Chung SJ, Jeon YJ, Park JT, Bang JS, Lee HS, Kim TY, Lee JJ, Hong YS.
    Org Biomol Chem; 2008 Jan 21; 6(2):340-8. PubMed ID: 18175003
    [Abstract] [Full Text] [Related]

  • 8. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug 21; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 9. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
    Zhang MQ, Gaisser S, Nur-E-Alam M, Sheehan LS, Vousden WA, Gaitatzis N, Peck G, Coates NJ, Moss SJ, Radzom M, Foster TA, Sheridan RM, Gregory MA, Roe SM, Prodromou C, Pearl L, Boyd SM, Wilkinson B, Martin CJ.
    J Med Chem; 2008 Sep 25; 51(18):5494-7. PubMed ID: 18800759
    [Abstract] [Full Text] [Related]

  • 10. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV, Workman P.
    Endocr Relat Cancer; 2006 Dec 25; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z, Jia L, Wang J, Wu X, Hao H, Xu H, Wu Y, Shi G, Lu C, Shen Y.
    Eur J Med Chem; 2014 Oct 06; 85():359-70. PubMed ID: 25105924
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G, Wang M, Welch TR, Blagg BS.
    J Org Chem; 2006 Sep 29; 71(20):7618-31. PubMed ID: 16995666
    [Abstract] [Full Text] [Related]

  • 13. [Progress in the study of heat shock protein 90 inhibitors].
    Luo HM, Sun W, Yin JY, Yang XH.
    Yao Xue Xue Bao; 2010 Jul 29; 45(7):813-20. PubMed ID: 20931776
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 15. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ, Margaritis LH, Voutsinas GE.
    Curr Med Chem; 2007 Jul 15; 14(29):3122-38. PubMed ID: 18220746
    [Abstract] [Full Text] [Related]

  • 16. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C.
    Expert Opin Investig Drugs; 2009 Jun 15; 18(6):861-8. PubMed ID: 19466875
    [Abstract] [Full Text] [Related]

  • 17. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS, Proisy N, Davis CJ, Boland NA, Sharp SY, Boxall K, Slawin AM, Workman P, Moody CJ.
    Org Biomol Chem; 2007 Feb 07; 5(3):531-46. PubMed ID: 17252137
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ.
    J Med Chem; 2006 Jul 27; 49(15):4606-15. PubMed ID: 16854066
    [Abstract] [Full Text] [Related]

  • 19. Fluorine- and rhenium-containing geldanamycin derivatives as leads for the development of molecular probes for imaging Hsp90.
    Wuest F, Bouvet V, Mai B, LaPointe P.
    Org Biomol Chem; 2012 Sep 07; 10(33):6724-31. PubMed ID: 22825378
    [Abstract] [Full Text] [Related]

  • 20. Convergent synthesis and discovery of a natural product-inspired paralog-selective Hsp90 inhibitor.
    Jeso V, Cherry L, Macklin TK, Pan SC, LoGrasso PV, Micalizio GC.
    Org Lett; 2011 Oct 07; 13(19):5108-11. PubMed ID: 21866939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.